Soleno Therapeutics, Inc. (NASDAQ:SLNO) Position Increased by Altium Capital Management LLC

Altium Capital Management LLC increased its stake in Soleno Therapeutics, Inc. (NASDAQ:SLNO - Free Report) by 17.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 250,000 shares of the company's stock after buying an additional 37,091 shares during the period. Soleno Therapeutics accounts for about 3.2% of Altium Capital Management LLC's portfolio, making the stock its 9th largest position. Altium Capital Management LLC owned 0.58% of Soleno Therapeutics worth $11,238,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in Soleno Therapeutics by 19.2% in the fourth quarter. Vanguard Group Inc. now owns 1,884,533 shares of the company's stock worth $84,710,000 after buying an additional 303,806 shares in the last quarter. State Street Corp boosted its position in Soleno Therapeutics by 14.2% during the third quarter. State Street Corp now owns 1,142,169 shares of the company's stock valued at $57,668,000 after purchasing an additional 142,033 shares in the last quarter. Pictet Asset Management Holding SA lifted its position in shares of Soleno Therapeutics by 48.0% during the fourth quarter. Pictet Asset Management Holding SA now owns 851,838 shares of the company's stock valued at $38,290,000 after buying an additional 276,225 shares during the last quarter. Wellington Management Group LLP grew its position in shares of Soleno Therapeutics by 14.5% in the 4th quarter. Wellington Management Group LLP now owns 782,265 shares of the company's stock worth $35,163,000 after buying an additional 99,095 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Soleno Therapeutics by 10.9% during the 4th quarter. Geode Capital Management LLC now owns 599,119 shares of the company's stock worth $26,937,000 after acquiring an additional 58,823 shares in the last quarter. Institutional investors own 97.42% of the company's stock.

Insiders Place Their Bets

In other news, insider Patricia C. Hirano sold 3,782 shares of the company's stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $70.11, for a total value of $265,156.02. Following the completion of the sale, the insider now directly owns 27,036 shares of the company's stock, valued at approximately $1,895,493.96. This represents a 12.27 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Bhatnagar Anish sold 699,095 shares of the business's stock in a transaction dated Thursday, March 27th. The shares were sold at an average price of $67.62, for a total value of $47,272,803.90. Following the completion of the transaction, the chief executive officer now owns 577,076 shares in the company, valued at $39,021,879.12. This trade represents a 54.78 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 942,672 shares of company stock valued at $64,058,781 in the last ninety days. Insiders own 12.30% of the company's stock.

Soleno Therapeutics Trading Up 3.4 %

Soleno Therapeutics stock traded up $2.31 during mid-day trading on Tuesday, hitting $71.24. The company's stock had a trading volume of 328,551 shares, compared to its average volume of 723,212. The firm has a market capitalization of $3.27 billion, a PE ratio of -21.51 and a beta of -2.29. Soleno Therapeutics, Inc. has a 1 year low of $36.93 and a 1 year high of $74.00. The stock's fifty day moving average is $55.54 and its two-hundred day moving average is $52.25.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last announced its quarterly earnings data on Wednesday, March 5th. The company reported ($1.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.41). On average, equities analysts expect that Soleno Therapeutics, Inc. will post -3.72 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on SLNO. Stifel Nicolaus boosted their target price on shares of Soleno Therapeutics from $74.00 to $108.00 and gave the stock a "buy" rating in a research report on Friday, March 28th. Robert W. Baird boosted their target price on shares of Soleno Therapeutics from $72.00 to $102.00 and gave the company an "outperform" rating in a research note on Thursday, March 27th. Guggenheim reiterated a "buy" rating and set a $81.00 price target (up previously from $70.00) on shares of Soleno Therapeutics in a research report on Friday, March 28th. Cantor Fitzgerald lifted their target price on shares of Soleno Therapeutics from $67.00 to $123.00 and gave the company an "overweight" rating in a research report on Thursday, March 27th. Finally, HC Wainwright reiterated a "buy" rating and set a $100.00 price target on shares of Soleno Therapeutics in a research report on Tuesday, April 15th. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $99.63.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.